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Alzheimer disease (AD) is the most frequent form of 
dementia in the elderly without an effective disease- 
modifying therapy.1 Accumulation of extracellular plaques 
of β-amyloid (Aβ) protein and intracellular neurofibrillary 
tangles of hyperphosphorylated tau protein in brain are the 
major pathological AD hallmarks and, in accordance, the 
main drug targets for AD drug development today.1 
Nevertheless, dysregulated intracellular calcium homeosta-
sis is proposed as an early key event in AD pathogenesis 
that underlies the disease hallmarks and associated cogni-
tive deficits.2–5 In fact, impaired calcium homeostasis has 
been shown to trigger and accelerate Aβ and tangle patholo-
gies6,7 while also mediating synaptic failure and neuron 
loss.8,9 Therefore, pharmacological reversal of calcium dys-
homeostasis potentially represents an alternative viable 
approach for AD therapy. Hence, we aimed at stabilizing 
intracellular store calcium homeostasis, particularly in the 
endoplasmic reticulum (ER), as an innovative target for AD 
drug discovery. To that end, we developed a high-through-
put calcium imaging assay, screened a library of 20,000 
small molecules, and identified four lead structures that 
reversed the familial AD-linked mutant presenilin 1 (FAD-
PS1)–mediated impairment of ER calcium homeostasis.
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Abstract
Perturbed intracellular store calcium homeostasis is suggested to play a major role in the pathophysiology of Alzheimer disease 
(AD). A number of mechanisms have been suggested to underlie the impairment of endoplasmic reticulum calcium homeostasis 
associated with familial AD-linked presenilin 1 mutations (FAD-PS1). Without aiming at specifically targeting any of those 
pathophysiological mechanisms in particular, we rather performed a high-throughput phenotypic screen to identify compounds 
that can reverse the exaggerated agonist-evoked endoplasmic reticulum calcium release phenotype in HEK293 cells expressing 
FAD-PS1. For that purpose, we developed a fully automated high-throughput calcium imaging assay using a fluorescence resonance 
energy transfer–based calcium indicator at single-cell resolution. This novel robust assay offers a number of advantages compared 
with the conventional calcium measurement screening technologies. The assay was employed in a large-scale screen with a library 
of diverse compounds comprising 20,000 low-molecular-weight molecules, which resulted in the identification of 52 primary hits 
and 4 lead structures. In a secondary assay, several hits were found to alter the amyloid β (Aβ) production. In view of the recent 
failure of AD drug candidates identified by target-based approaches, such a phenotypic drug discovery paradigm may present an 
attractive alternative for the identification of novel AD therapeutics.
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Materials and Methods
Cell Culture and Cell Lines
Human embryonic kidney 293 (HEK293) cells were cul-
tured as previously described.10 The PS1 lines were 
then stably transfected with YC3.6/pcDNA3 construct 
(kindly provided by Dr. A. Miyawaki), and clones were 
respectively isolated by G418 antibiotic resistance.11 The 
HEK293 APPsw/PS1-M146L line was kindly provided by 
Dr. H. Steiner and cultured as previously described.12
Compound Library
DIVERSet 1 and 2 libraries (ChemBridge Corp., San Diego, 
CA), each containing a diverse collection of 10,000 hand-
synthesized small molecules (in total 20,000 compounds), 
were used for high-throughput compound screening. 
Compounds fulfilled the “Lipinski’s rule of 5,” indicating 
their high druglikeness potential.13
High-Throughput Calcium Imaging Assay
For the primary screen, HEK293 cells stably expressing PS1-
M146L and Yellow Cameleon 3.6 (YC3.6) were seeded at 
13,000 cells/well in 40 µL of growth medium on collagen-
coated 384-well CellCarrier plates (PerkinElmer, Rodgau, 
Germany). After 6 h, using an automated pipetting robot 
(Bravo; Agilent Technologies, Santa Clara, CA), library com-
pounds were added to each well at the final concentration of 
10 µM in 1% DMSO, each in four replicates. All plates con-
tained Thapsigargin (TP; 1 µM; Calbiochem, Darmstadt, 
Germany), cyclopiazonic acid (CPA; 20 µM; Calbiochem), 
and 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester 
(TMB-8; 50 µM; Sigma-Aldrich, Taufkirchen, Germany) as 
positive controls, as well as untreated and DMSO vehicle-
treated wells. After 24 h using the pipetting robot, DRAQ5 
(Biostatus Ltd, Leicestershire, UK), a far-red fluorescent 
nuclear dye, was added to each well at the final concentration 
of 500 nM. After 2 h, plates were measured for carbachol 
(CCh)–induced calcium release using the Opera high-through-
put confocal imaging platform (PerkinElmer Cellular 
Technologies GmbH, Hamburg, Germany). Throughout imag-
ing of the entire plate, 37 °C temperature, 5% CO2, and 90% 
humidity were maintained in the plate chamber. Using a 442-
nm laser, YC3.6 was excited and its cyan fluorescent protein 
(CFP) and yellow fluorescent protein (YFP) emissions were 
separated respectively using 483/35-nm and 540/75-nm filters. 
In addition, using a 640-nm laser, DRAQ5 dye was excited 
and its emission was collected by a 690/50-nm filter to locate 
the nuclei. Imaging was performed with a 20× water immer-
sion autofocus objective. The duration of the entire time-lapse 
calcium imaging for each well was 23.5 s. This was achieved 
by imaging at a 2.5-s interval resolution prior to dispensing 
CCh (for 5 s) to monitor the basal calcium levels. Next, the 
CCh-induced calcium rise and decay was monitored for 18.5 s 
after dispensing. Imaging was performed first at a 1-s interval 
resolution immediately after dispensing (for 5 s) and subse-
quently at a 2.5-s interval resolution (for 12.5 s). During dis-
pensing, 10 µL CCh (Calbiochem) diluted in Hank’s balanced 
salt solution (HBSS; 10 µM) was injected into each well con-
current with calcium imaging by an automated dispensing unit, 
which is part of the Opera platform. Imaging was performed 
sequentially in all 384 wells.
Data Mining
Data mining, clustering, and identification of the lead struc-
tures were performed with the Benchware DataMiner soft-
ware (Tripos, St. Louis, MO).
Cytotoxcity Assay
The cytotoxicity of the compounds was assessed in vitro using 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) cell proliferation assay kit (Roche Diagnostics 
GmbH, Mannheim, Germany) according to the manufactur-
er’s instructions and previously described protocols.14
Aβ Measurements
Levels of three different Aβ species (Aβ38, Aβ40, and 
Aβ42) were measured using sandwich enzyme-linked 
immunosorbent assay (ELISA). Pools of HEK293 cells sta-
bly transfected with APPsw/PS1-M146L were used to study 
the effect of compounds on Aβ generation. According to 
Page et al.,12 cells were seeded at a density of 200,000 cells/
well in collagen/poly-L-lysine (PLL)–coated 24-well plates 
and incubated for 24 h in growth medium. Next, the medium 
was exchanged with 500 µL of fresh medium containing the 
compounds, the positive control DAPT (10 µM; 
Calbiochem), or DMSO vehicle. After 16 h, conditioned 
medium was collected and the levels of secreted Aβ38, 
Aβ40, and Aβ42 fragments were quantified using the 
“Human (6E10) Abeta 3-Plex” sandwich ELISA immuno-
assay kit (Meso Scale Discovery, Rockville, MD) according 
to the instructions of the manufacturer. The light emission 
after electrochemical stimulation was measured using the 
Sector Imager 2400 reader (Meso Scale Discovery). Based 
on the values generated with calibration standards, corre-
sponding concentrations of Aβ species were calculated 
using the Meso Scale Discovery Workbench software. All 
measurements were performed in four replicates.
Statistical Data Analysis
GraphPad Prism 5.0b (GraphPad Software, San Diego, CA) 
was used for statistical analysis of the data. Values represent 
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mean ± standard deviation. To test significance, a two-tailed 
Student t test was performed and differences were consid-
ered statistically significant if p < 0.05.
Results
FRET-Based Calcium Imaging Using YC3.6
YC3.6, a superior genetically encoded fluorescence reso-
nance energy transfer (FRET)–based calcium indicator with 
predominant cytosolic localization, expanded dynamic range, 
and fast kinetics,11 was introduced to HEK293 cells as a tool 
to monitor both the basal calcium concentrations and the 
released calcium from ER in real time by confocal imaging. 
YC3.6 is composed of CFP and YFP domains, linked via 
calmodulin (CaM) and a CaM-binding peptide (M13). Upon 
calcium binding, it undergoes a conformational change and 
thereby FRET efficiency increases (Fig. 1A).11
The assay readout was the peak response of inosi-
tol-1,4,5-trisphosphate receptor (IP3R)–evoked calcium 
release from ER. Agonist-induced IP3 production by CCh 
results in calcium release from ER (Fig. 1B). The release of 
calcium from ER into the cytosol results in rise of calcium 
concentration that can be monitored by increased FRET 
efficiency.
Time-lapse calcium imaging indicates that within a few 
seconds after dispensing CCh, FRET efficiency rapidly 
increases—that is, the CFP (FRET donor) signal decreases, 
while the YFP signal (FRET acceptor) increments 
(Fig. 1C,D, upper panel).
In Figure 1C, the acceptor-donor signals of all cells in a 
single well are shown for two time points. One set of points 
are single-cell signals before dispensing, and the other set 
of points are the signals 3 s after dispensing. The slope of 
the distribution corresponds to the FRET signal, which is 
calculated as the ratio of the YFP to CFP signal. The change 
in FRET efficiency after stimulating with CCh is clearly 
visible in the change of distribution slope (Fig. 1C). In 
accordance, the FRET ratio (YFP/CFP) can be used as a 
tool to monitor calcium dynamics (Fig. 1D, lower panel). 
Following the rise in calcium concentration, the peak of cal-
cium release is reached. After the peak, the FRET ratio 
begins to decay as a result of calcium buffering and seques-
tration (Fig. 1D).
FAD-PS1 Mutations Enhance the Amplitude of 
CCh-Induced Calcium Release and the Number 
of CCh-Responsive Cells
Mutations in presenilins (PS1 and PS2) account for the vast 
majority of early onset familial Alzheimer disease (FAD) 
cases. These mutations result in increased IP3R sensitivity.
15 
Moreover, function of multiple upstream elements of IP3 
receptor-mediated calcium release is also affected in 
AD—for example, G-protein–coupled receptors (GPCRs) 
in general16 and muscarinic receptors in particular,17 
G-proteins,18 and phospholipase C (PLC).19 Presumably, 
the combination of those results in a remarkably greater 
IP3R-mediated calcium release in FAD-PS1 cells. Since the 
screening hits may potentially target any of those upstream 
elements, such a phenotypic multitargeted drug screening 
paradigm allows collectively addressing several aspects of 
AD.
Indeed, using the developed FRET-based calcium imag-
ing assay, we could confirm the exaggerated CCh-evoked 
ER calcium release signals in cells expressing different 
mutant forms of PS1 (Fig. 1E). The peak response of CCh-
evoked calcium release and the number of CCh-responsive 
cells were remarkably higher in FAD-PS1 lines (PS1-
M146L, PS1-C92S, PS1-DeltaE9) compared with the wild-
type PS1 line (Fig. 1F,G). Likewise, the expression of a 
γ-secretase–deficient mutant form of PS1 (PS1-D385N) 
results in increased responsiveness to CCh and augmented 
calcium release from ER upon CCh stimulation (Fig. 1F,G). 
To assess the single-cell resolution of the assay, the traces 
for individual cells showing the raw and normalized FRET 
ratio changes (CCh-evoked calcium responses) are plotted 
for cells expressing either wild-type or mutant forms of PS1 
(Suppl. Fig. S1). By looking at the single-cell traces, par-
ticularly in cells expressing wild-type PS1, a large natural 
variability in peak amplitudes of calcium response is evi-
dent (Suppl. Fig. S1). This is likely to be caused by the 
natural lower sensitivity of IP3R gating at suboptimal con-
centrations of IP3 as well as the smaller scale of calcium 
release in wild-type PS1 versus FAD-PS1 cells.15
Therefore, the augmented CCh-evoked calcium release 
in FAD-PS1–expressing cells was used as a robust pheno-
typic readout in a high-throughput screening (HTS) 
approach, which aimed at identification of drugs that can 
reverse the exaggerated calcium release to physiological 
levels (Suppl. Fig. S3A). Active compounds would affect 
the latter phenotypic readout by potentially targeting the 
IP3R sensitivity, the upstream elements of IP3R-evoked 
calcium release (muscarinic receptors, GPCRs, and PLC), 
or calcium channels and pumps on the ER membrane. 
Moreover, compounds that directly affect the ER calcium 
load can also be identified in this screening paradigm. 
The latter is particularly important, as the ER calcium 
load is suggested to be altered in the pathophysiology of 
AD.3,20
Assay Development
We addressed intracellular store calcium dyshomeostasis as 
an innovative target for drug discovery with a novel FRET 
single-cell–based calcium imaging technique in a fully 
automated high-throughput kinetic assay on the Opera 
system (PerkinElmer) for compound screening.
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Figure 1. Fluorescence resonance energy transfer (FRET)–based calcium imaging with Yellow Cameleon 3.6 (YC3.6). (A) Structure 
of the calcium sensor YC3.6 that is a fusion protein composed of cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) 
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The assay readout was the potentiated IP3R-evoked cal-
cium response in HEK293 cells expressing a FAD-linked 
mutation, PS1-M146L. Indeed, treatment with three different 
positive controls (TP, CPA, and TMB-8) resulted in decreased 
CCh-evoked calcium release from the ER (Fig. 1H).
The dose-dependent effect of CCh in increasing the peak 
amplitude of calcium response was evaluated across a range 
of different CCh concentrations in PS1-M146L cells 
(Fig. 1I). Indeed, pretreatment with TP lowered the peak 
amplitude of the ER calcium response in all CCh concentra-
tions tested (Fig. 1I). Moreover, the dose-dependent effect 
of TP in lowering the peak amplitude of CCh-induced cal-
cium release was investigated (CCh: 10 µM) (Fig. 1J).
Image Analysis
The image analysis software Acapella (PerkinElmer) was 
used to convert the time-lapse images into numerical val-
ues. Acapella is a scripting-based solution for implementing 
different requirements on the image analysis side. The 
image analysis consisted of four steps: segmenting the 
image into the individual cells, determining the time-depen-
dent signals for each identified cell, processing the signals 
of each cell, and then classifying cells and reporting rele-
vant results (Fig. 2A).
Image segmentation. For the segmentation, the nuclei and 
CFP images of the first time point were used. The segmen-
tation of the nuclei image was done with the nuclei_
detection_B() algorithm of the Acapella, which involves 
automatic threshold calculations and some masking steps to 
split nuclei in close proximities along lines of darker pixels. 
For each detected nucleus (based on DRAQ5 signal), the 
CFP signal for that time point was also determined. The 
nuclei with a signal below a certain threshold were excluded 
from image analysis. In addition, the CFP signal after dis-
pensing CCh was measured to detect and exclude the cells 
that were washed away in the well due to dispensing.
Starting from the initially segmented nuclei, the cyto-
plasm_detection_c() algorithm of Acapella was used to 
determine the location and shape of the cells using the CFP 
image. Here again, threshold calculations were used by 
Acapella to define the final cell shape. In addition, we 
excluded the cells located at the edges of the image (image 
borders) to minimize the potential of artifacts caused by 
only partially visible cells.
For the short time series as used in this HTS approach, 
the motility of the cells can be neglected. We compared the 
covered areas by the cells when the detection algorithm was 
applied to the first and a later time point. In Figure 2B, the 
detected cell areas are outlined for time points at t = −5 s 
and at t = 1 s (times are relative to the dispensing time). 
Also shown are the “overlap area” between the two time 
points, as well as the area that is only detected at t = −5 s 
(“lost area”) and at t = 1 s (“gained area”). The size of these 
areas (normalized to the size at t = −5 s) is presented over 
the entire course of time-lapse calcium imaging for PS1-
M146L cells (Fig. 2B). Similarly, the changes in the over-
lap, gained, and the lost areas for DMSO- or positive 
control-treated cells are shown (Suppl. Fig. S2). All curves 
show a predominant change between t = 0 s and t = 1 s, 
indicating that dispensing of CCh into the wells may cause 
a mechanical stress, causing changes in the covered cell 
areas. However, these changes were often small, as the val-
ues for the lost and gained areas were approximately on the 
order of 4% to 5%. Therefore, we decided to neglect such 
small area changes within the short period of time-lapse cal-
cium imaging. However, for longer kinetic experiments, it 
might be necessary to adjust the cell boundaries for each 
time point.
Measuring signals. As presented in Figure 1D (and Suppl. 
Videos S1 and S2), calcium-dependent changes in FRET 
are shown upon stimulation with CCh (shown either as the 
merged image of donor shown in blue and acceptor in yel-
low or FRET ratio signal in gray scale). In the color images, 
attached via calmodulin (CaM) and a CaM-binding peptide (M13). Calcium binding brings CFP and YFP together, shifting the emission 
of 480 nm to 535 nm upon excitation at 440 nm. (B) Carbachol (CCh) application initiates a pathway, which results in calcium release 
from the endoplasmic reticulum (ER). CCh exposure leads to G-coupled activation of phospholipase C (PLC), catalyzing the hydrolysis 
of the membrane-associated PIP2 molecule to IP3. Binding of the IP3 molecule to IP3 receptor channels (IP3R) on the ER membrane in 
turn leads to opening of IP3R channels and calcium release from the ER to the cytosol. (C) FRET acceptor-donor distribution signal 
before (green) and after (red) dispensing CCh. The slope of the distribution corresponds to the FRET signal, which is calculated as 
the ratio of the YFP over CFP signal. (D) Representative calcium-dependent changes in FRET are shown upon stimulation with CCh. 
Upper panel shows the merged image of FRET donor (blue) and acceptor (yellow). The lower panel shows the FRET ratio signal in 
gray scale. (E) Representative calcium transients of CCh-evoked calcium release in cells expressing mutant variants versus wild-type 
presenilin (PS) upon CCh application. (F) The average peak amplitude of CCh-induced calcium release is significantly potentiated in 
familial Alzheimer disease (FAD) and inactive PS1 mutants compared with wild-type PS1 cells (***p < 0.001). (G) The average number 
of responsive cells to CCh is remarkably increased in cells expressing FAD and inactive PS1 mutants compared with wild-type PS1 
cells (***p < 0.001). (H) Representative calcium transients of CCh-evoked calcium release in PS1-M146L HEK293 cells treated with 
carrier DMSO or positive controls cyclopiazonic acid (CPA), 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester (TMB-8), and 
thapsigargin (TP). (I) Dose-response effect of CCh agonist on the peak amplitude of calcium release in untreated or TP-treated PS1-
M146L cells. (J) Dose-dependent effects of TP on the peak amplitude of CCh-evoked calcium release in PS1-M146L cells.
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Figure 2. Image analysis workflow and detected cell area change over the course of time-lapse imaging. (A) Initially, all the nuclei from 
the images of the first time point are segmented (based on DRAQ5 signal). For each detected nucleus, the corresponding cyan fluorescent 
protein (CFP) signals are determined at the first time point. Next, the cells located at the edges of image are excluded. The minimal motility 
of the cells during the course of imaging is neglected, and the intensity changes inside of the cell areas detected at the first time point are 
monitored over time (upper panel). Fluorescence resonance energy transfer (FRET) donor, acceptor, raw FRET, normalized FRET, and 
average FRET response traces to carbachol (CCh; 10 µM) are presented (middle and lower panels). The orange dashed line represents 
the arbitrarily defined threshold of responsiveness. The red and green curves respectively correspond to the average calcium release of 
responsive and nonresponsive cells. (B) The detected cell areas for time points at t = −5 s (first time point) and at t = 1 s (after dispensing) 
are shown. Also shown are overlap, gained, and lost areas between the two time points. The size of overlap, gained, and lost areas 
(normalized to the size at t = −5 s) is presented over the entire course of time-lapse calcium imaging for PS1-M146L cells.
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the nuclei are visible as areas of lower fluorescence signal. 
However, in the FRET ratio images, the nuclei are not 
clearly visible anymore, indicating that the FRET efficiency 
is homogeneous throughout the cell body.
Processing the cell signals. For each cell, the average FRET 
ratio before dispensing was determined as an individual off-
set value. From the measured FRET signals, this offset was 
subtracted, so that we obtain the FRET signal changes rela-
tive to the predispensing condition. In addition, also the 
shape of the FRET signal change over time can be evalu-
ated. In particular, both the amplitude of the “maximum” 
FRET efficiency, as well as the “time” at which this maxi-
mum response is reached, can be analyzed.
For example, in the wild-type PS1 cells, after approxi-
mately a 6-s delay from dispensing CCh, the peak of FRET 
response was reached. However, in FAD-PS1 cells, the FRET 
peak response delay was shorter (depending on the mutation, 
peak of FRET response was reached within 1–4 s after dis-
pensing CCh) (Fig. 1E). In other words, FAD-PS1 mutations 
enhance the calcium release from the ER, while also shorten-
ing the latency of calcium release after dispensing CCh. On the 
other hand, positive controls CPA and TMB-8 further extended 
this latency in PS1-M146L cells (Fig. 1H).
Classification of cells. For every cell, the maximum increase 
of the FRET signal and the time point at which this maxi-
mum is reached are determined. The cells are classified into 
responsive and nonresponsive cells based on an arbitrarily 
defined threshold value and whether the peak FRET value 
lies below or above that threshold.
High-Throughput Compound Screening 
Workflow
As illustrated in Supplemental Figure S4, HEK293 cells 
stably coexpressing the FAD-linked PS1-M146L mutation 
and YC3.6 were seeded on 384-well optical bottom plates. 
After 6 h, compounds from the library plates were distrib-
uted into separate wells by automated pipetting. After 24 h 
compound incubation, DRAQ5 nuclear marker was added 
to the wells. After 2 h, time-lapse calcium imaging was per-
formed and CCh-induced calcium release was monitored 
sequentially for each well using the YC3.6 calcium indica-
tor. In addition, the signal of DRAQ5 dye was also collected 
throughout the entire course of time-lapse imaging, which 
was necessary for image analysis. For every detected cell, 
calcium transients were measured over the course of imag-
ing by calculating and normalizing the YFP/CFP ratios. The 
peak response amplitude of the calcium rise upon CCh 
injection was the output of automated analysis at a single-
cell level. CCh nonresponsive cells were excluded from the 
analysis by setting an arbitrarily defined threshold. The 
average peak amplitude of all responsive cells in a well was 
calculated as the final output of the image analysis.
The performance of the high-throughput compound 
screening assay remained very robust throughout screening 
of 200 plates (Z′ factor > 0.8). Z′ factors for 10 randomly 
selected plates are presented in Supplemental Figure S3B. 
The average Z′ factor for those 10 plates was determined to 
be 0.806 ± 0.029, reflecting the robustness of the assay for 
HTS.
High-Throughput Compound Screening Assay 
Enables the Discovery of Novel Lead Structures
After filtering the autofluorescent and highly toxic com-
pounds, the primary screen yielded 52 hits (Fig. 3). A com-
pound was regarded as a hit if the peak response of calcium 
release in cells treated with that compound was <90% of 
that in DMSO-treated controls. To each library compound, 
a score typically <1.0 was assigned indicating a measure for 
its efficacy, calculated by dividing the peak response of cal-
cium release in cells treated with that given compound to 
the peak response of DMSO-treated controls on the same 
plate. Hereafter, we refer to this value as the “normalized 
ER calcium response score.” In Figure 3, a list of all hits 
from the primary screen, including their chemical structures 
and corresponding normalized ER calcium response scores, 
is presented.
The activity of all primary hits was validated in PS1-M146L 
cells and confirmed in two other FAD-PS1 lines (PS1-C92S 
and PS1-DeltaE9) (Fig. 4A and Suppl. Fig. S6). Fifty-two 
structures identified from the primary screen were classified 
into different categories based on their efficacy (Suppl. Fig. 
S5). These categories are separated according to the corre-
sponding values of the normalized ER calcium response score, 
presented as percentages in relation to the peak response of the 
DMSO-treated control.
Preliminary structure-activity relationship (SAR) assess-
ments led to the identification of four lead structures. Those 
structures belonged to the following classes of compounds: 
thiazolidine, phenothiazine, imidazole, and benzhydrilpi-
peridinamine (Suppl. Figs. S7–S11). A SAR map of the 
clusters was generated, where clusters with more than 50% 
active compounds were represented as stars and clusters 
with less than 50% active compounds as rectangles. In addi-
tion, all clusters with more than four active compounds 
were colored in blue and otherwise in red. The sizes of the 
symbols correlate directly with the number of compounds 
in each cluster (Suppl. Fig. S7).
In the MTT assay, most hits showed no toxicity. HEK293 
cells treated with the hits at 10 µM for 24 h remained viable 
(Fig. 4B). Treatment with only five compounds, three of 
which belonged to the thiazolidine lead structure, resulted 
in a 30% to 40% reduction in cellular viability.
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Figure 3. Active structures identified from the primary high-throughput screen. Shown are 52 small molecules identified from the 
primary screen with their chemical structure and the corresponding normalized mean endoplasmic reticulum (ER) calcium response ± 
standard deviation values generated at 10 µM as a measure for their activity.
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Figure 4. Validation of primary hits and their in vitro cytotoxicity. (A) The activity of all 52 primary hits was validated in the PS1-
M146L line. All the hits were capable of reducing the peak response of carbachol (CCh)–induced calcium release to <90% of DMSO-
treated controls. The peak response of the DMSO-treated control was set to 1. (B) Viability of HEK293 cells treated with the primary 
screen hits was assessed by means of the MTT assay after a 24-h compound treatment. Values are presented as percentage of viable 
cells. The data for analogous molecules belonging to the same lead structure are marked with the same color.
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Effect of Hits on Aβ Generation
Modulation of calcium homeostasis affects the production 
to amyloid β (Aβ) peptide, the major constituent of the 
amyloid plaques in the AD brain.6 Furthermore, we also 
tested the effects of primary screen hits on Aβ peptide pro-
duction. Depending on the compound tested, we detected 
increased, decreased, or unchanged Aβ levels upon 16-h 
exposure of HEK293 APPsw/PS1-M146L cells with the 
compounds (Fig. 5).
Discussion
Here we describe the development and implementation of a 
high-throughput compound screening assay targeting ER 
calcium dysregulation as an innovative approach for AD 
drug discovery. As opposed to the majority of AD drug dis-
covery strategies that target late-stage disease hallmarks, 
this approach targets a cellular event that is proposed to 
occur early in the pathophysiology of AD.2
Various mechanisms have been proposed to underlie the 
FAD-PS1–mediated enhancement of the ER calcium release—
for example, enhanced IP3 and ryanodine receptor (RyR) chan-
nel activities,15,21 altered sarcoendoplasmic reticulum calcium 
ATPase (SERCA) pump function,22 decreased store-operated 
calcium entry (SOCE),23 and loss of PS holoprotein passive 
calcium leakage.20 Irrespective as to which of those are the pri-
mary causative and which the secondary phenomena, we per-
formed a phenotypic compound screen and identified small 
molecules that reverse the exaggerated calcium release from 
ER in cells expressing a FAD-PS1 mutation.
The HTS assay developed offers several advantages com-
pared with current calcium measurement screening technolo-
gies. First, the use of genetically encoded calcium sensors as 
opposed to conventional synthetic calcium-sensitive dyes 
allows monitoring intracellular calcium dynamics without the 
drawbacks caused by dye toxicity, loading, washing, and leak-
age. Second, the developed HTS assay allows performing 
rapid automated dispensing of reagent jets to individual wells 
during calcium measurements with no time lag between dis-
pensing and imaging. The latter is ideal for kinetic measure-
ments that require rapid imaging with no delay after dispensing 
(e.g., fast agonist-induced calcium release). Third and most 
important, as opposed to single-well–based calcium measure-
ment systems, the single-cell–based nature of this assay in 
combination with automated image analysis enables simulta-
neous monitoring of calcium transients in individual cells of a 
well and applying multiple filtering parameters in image anal-
ysis to set apart different cell subpopulations. Furthermore, 
the assay offers a competitive robustness reflected by a Z′ 
Figure 5. Effects of the active compounds from the calcium high-throughput screening (HTS) on Aβ production. Altered production 
of Aβ38, Aβ40, and Aβ42 after a 16-h treatment of HEK293 cells coexpressing APPsw and PS1-M146L with the active structures 
identified from the calcium HTS. DAPT (10 µM) was used as a γ-secretase inhibitor control.
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factor >0.8. An obvious limitation of this assay is, however, 
the difficulty of calibrating the FRET signals to actual calcium 
concentrations. Yet for HTS purposes, with a suitable signal 
window, it is often not necessary to measure the absolute cal-
cium concentrations.
Calcium alterations associated with FAD-PS expression 
provide ideal means to investigate the disruption of ER 
calcium homeostasis. FAD-PS–dependent calcium altera-
tions in intracellular calcium stores have been linked to syn-
aptic dysfunction, which is the underlying basis for 
cognitive impairment in AD.24 Screening of 20,000 small 
molecules using the HTS assay yielded the discovery of 52 
primary hits, from which 4 lead structures were identified 
that belonged to the classes of compounds: thiazolidine, 
phenothiazine, imidazole, and benzhydrilpiperidinamine. 
Notably, existing evidence supports the beneficial effects of 
phenothiazine and thiazolidine derivatives for treatment of 
AD.25–27 Such indications validate the relevance of this phe-
notypic screening strategy as well as the lead structures 
identified from it.
Alterations in intracellular calcium homeostasis can 
directly affect Aβ production.6 Indeed, many of the active 
compounds identified from the primary calcium screen either 
increased or decreased the production of Aβ peptides. Such a 
broad range of effects on Aβ generation is most likely caused 
by targeting different components of intracellular calcium 
homeostasis by different hits. Indeed, calcium ions have been 
shown to directly regulate the activity of secretases.28,29
As it is typical for phenotypic drug screening approaches, 
the molecular targets of these hits are yet to be determined. 
However, we speculate that, some of the hits may dampen 
the hyperactivated calcium channels located on the ER,15,21 
modulate the PS holoprotein passive calcium leak channel 
activity,20 or target the upstream elements involved in IP3R-
evoked calcium release,15–17,19 thereby normalizing the dis-
turbed ER calcium homeostasis.
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